Showing 641 - 660 results of 1,930 for search 'ocarina~', query time: 3.75s Refine Results
  1. 641
  2. 642
  3. 643
  4. 644
  5. 645
  6. 646
  7. 647
  8. 648
  9. 649
  10. 650
  11. 651
  12. 652
  13. 653
  14. 654

    Vascular Reconstructions in Living Unrelated Kidney Transplant Using Donor Ovarian Vein and Recipient Inferior Epigastric Artery with Simultaneous Enucleation of a Complex Cyst by Giuseppe Serena, Javier Gonzalez, Giselle Guerra, Mohamed Ammar Al Nuss, Maykel Valdes, Gaetano Ciancio

    Published 2019-01-01
    “…The renal vein was elongated using the donor ovarian vein and the short upper pole artery was extended using the recipient inferior epigastric artery and anastomosed to the main renal artery. …”
    Get full text
    Article
  15. 655
  16. 656

    Ovarian Vein Thrombosis Complicated by Pulmonary Embolism after Cesarean Delivery in the Presence of a Large Fibroid: Case Report and Literature Review of Contributing Factors by Elie S. Finianos, Stephanie F. Yacoub, Mary F. Chammas

    Published 2021-01-01
    “…Ovarian vein thrombophlebitis is rare and mostly occurs during the puerperal period and in higher rates after a cesarean delivery. …”
    Get full text
    Article
  17. 657
  18. 658
  19. 659
  20. 660

    The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial by Elena Giudice, Tzu-Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome, Marc R. Radke, Elizabeth M. Swisher, Stanley Lipkowitz, Kristen Ibanez, Duncan Donohue, Tyler Malys, Min-Jung Lee, Bernadette Redd, Elliot Levy, Shraddha Rastogi, Nahoko Sato, Jane B. Trepel, Jung-Min Lee

    Published 2024-03-01
    “…Abstract The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we report the activity of CHK1i in platinum-resistant high-grade serous ovarian carcinoma (HGSOC) with measurable and biopsiable disease (cohort 5), or without biopsiable disease (cohort 6). …”
    Get full text
    Article